BiotechTube

ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Painful Diabetic Peripheral Neuropathy (PDPN)

Conditions

Painful Diabetic Peripheral Neuropathy (PDPN)

Trial Timeline

May 27, 2015 → May 20, 2016

NCT ID
NCT02372578

About ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo

ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo is a phase 2 stage product being developed by Astellas Pharma for Painful Diabetic Peripheral Neuropathy (PDPN). The current trial status is terminated. This product is registered under clinical trial identifier NCT02372578. Target conditions include Painful Diabetic Peripheral Neuropathy (PDPN).

What happened to similar drugs?

7 of 20 similar drugs in Painful Diabetic Peripheral Neuropathy (PDPN) were approved

Approved (7) Terminated (2) Active (11)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅duloxetine hydrochlorideEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
✅pregabalinPfizerApproved
✅PregabalinPfizerApproved
✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02372578Phase 2Terminated

Competing Products

20 competing products in Painful Diabetic Peripheral Neuropathy (PDPN)

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
duloxetine hydrochlorideEli LillyApproved
43
Duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
43
Duloxetine + Pregabalin + PlaceboEli LillyPhase 3
40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mgEli LillyPhase 2
35
GRC 17356 + Matching PlaceboGlenmark PharmaceuticalsPhase 2
35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + PlaceboGlenmark PharmaceuticalsPhase 2
27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)Johnson & JohnsonPhase 3
32
AZD5213 + pregabalin + Placebo + pregabalin capsulesAstraZenecaPhase 2
35
MEDI7352AstraZenecaPhase 2
27
MEDI7352AstraZenecaPhase 2
35
MEDI7352 + PlaceboAstraZenecaPhase 1
29
MK-6096 + PlaceboMerckPhase 2
35
Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochlorideMerckPhase 2
27
EMA401 + PlaceboNovartisPhase 2
27
PregabalinPfizerPhase 3
40